DiaMedica Therapeutics Inc
Veridion Score
Composite trend over time
Why is DMAC moving today?
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for DMAC.
DMAC insider activity
DiaMedica Therapeutics Inc
No multi-insider buying cluster in the last 90 days
Net buying: $30.6M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-01-06 | 2026-01-02 | Semba Charles Pauling | Insider | buy | $8.42 | 3,355 | 47,963 | $28K | SEC Form 4 |
| 2026-01-06 | 2026-01-02 | Parsons James T. | Insider | buy | $8.42 | 10,095 | 97,949 | $85K | SEC Form 4 |
| 2026-01-06 | 2026-01-02 | Giuffre Randall Michael | Insider | buy | $8.42 | 6,175 | 398,587 | $52K | SEC Form 4 |
| 2025-12-08 | 2025-11-25 | TRILL AB | Insider | buy | $8.57 | 73,099 | 8,825,742 | $627K | SEC Form 4 |
| 2025-12-08 | 2025-11-24 | TRILL AB | Insider | buy | $7.89 | 40,253 | 8,752,643 | $318K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 18 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moDMAC contract awards, year to date.
Public federal awards linked to this ticker.
DMAC lobbying filings, year to date.
Registered lobbying filings matched to DiaMedica Therapeutics Inc.